Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
Linbin Lu, Peichan Zheng, Yan Pan, Shanshan Huang, Erqian Shao, Yan Huang, Xuewen Wang, Y. Chen, Gongbao Cuo, Hongyi Yang, Wangting Guo, Yanhong Shi, Zhixian Wu, Xiong Chen
Topics & Concepts
MedicineBevacizumabAtezolizumabInternal medicineHepatocellular carcinomaHazard ratioProportional hazards modelOncologyBiomarkerGastroenterologyConfidence intervalCancerImmunotherapyNivolumabChemotherapyBiochemistryChemistryHepatocellular Carcinoma Treatment and PrognosisOvarian cancer diagnosis and treatmentCancer Immunotherapy and Biomarkers